SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 4 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.

Recs

0
Player Avatar pchop123 (80.37) Submitted: 11/23/2012 11:48:31 AM : Outperform Start Price: $4.49 SCLN Score: -4.36

attractive new entry price especially with the prospect of a new acquisition

Featured Broker Partners


Advertisement